These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 38779641)

  • 1. Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Makri E; Goulas A; Xanthopoulos K; Polyzos SA
    Ann Gastroenterol; 2024; 37(3):280-290. PubMed ID: 38779641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Goulas A; Polyzos SA
    Eur J Pharmacol; 2021 Sep; 907():174272. PubMed ID: 34147478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
    Androutsakos T; Nasiri-Ansari N; Bakasis AD; Kyrou I; Efstathopoulos E; Randeva HS; Kassi E
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
    Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
    Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S; Jeong HE; Filion KB; Yu OH; Cho YM; Lee BH; Chang Y; Byrne CD; Shin JY
    JAMA Netw Open; 2023 Dec; 6(12):e2349856. PubMed ID: 38153732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
    Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
    J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease.
    Kontana A; Tziomalos K
    World J Gastroenterol; 2019 Jul; 25(28):3664-3668. PubMed ID: 31391764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Jung C; Park S; Kim H
    PLoS One; 2023; 18(11):e0294423. PubMed ID: 37992029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review.
    Xu R; Lian D; Xie Y; Chen Z; Wang Y; Mu L; Wang Y; Zhang B
    Front Biosci (Landmark Ed); 2023 Jul; 28(7):134. PubMed ID: 37525911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented duodenal levels of sodium/glucose co-transporter 1 are associated with higher risk of nonalcoholic fatty liver disease and noninvasive index of liver fibrosis.
    Fiorentino TV; De Vito F; Suraci E; Marasco R; Catalano F; Andreozzi F; Hribal ML; Luzza F; Sesti G
    Diabetes Res Clin Pract; 2022 Mar; 185():109789. PubMed ID: 35192912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
    Kothari S; Dhami-Shah H; Shah SR
    J Clin Exp Hepatol; 2019; 9(6):723-730. PubMed ID: 31889754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.